Pricing Log in Create free account
Friday 6 November 2026 Export LNTH’s income statement to Excel — free account

Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.

Revenue
+1.54%
EPS
−17.1%
Free cash flow
+7.71%
Total debt
+0.52%

Quarter to September 2026, against a year earlier

100.64 0.06 −0.06%
Market cap
$6.6B
P/E
24.3×
Fwd P/E
21.3×
Dividend yield
—
F-score
5/9
Altman Z
4.25
Beneish M
−2.23
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Lantheus Holdings, Inc. 8-K filed Jan 9, 2024

Period ended Jan 9, 2024 · Filed · accepted 7:57 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov